Sistema de Salut de Catalunya
Institut Català de la Salut
[Ciudin A] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Johansson E, Zimner-Rapuch S, Dimitriadis GK, Bertrand M] Eli Lilly and Company, Indianapolis, Indiana, USA. [Curteis T] Costello Medical, Manchester, UK
Vall d'Hebron Barcelona Hospital Campus
2025-09-22T10:49:56Z
2025-09-22T10:49:56Z
2025-09
Type 2 diabetes; Weight management
Diabetis tipus 2; Control del pes
Diabetes tipo 2; Control de peso
Aims This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2. Materials and Methods Participants had body mass index (BMI) ≥ 27 kg/m2, with ≥1 unsuccessful prior dietary weight reduction effort and glycated haemoglobin (HbA1c) 7%–10% on stable therapy. A heterogeneity assessment confirmed that study and patient baseline characteristics were similar. Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity. Results Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide. Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides. Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide. Conclusions In this ITC versus semaglutide 2.4 mg, tirzepatide 10 and 15 mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15 mg with statistically significant improvements in multiple cardiometabolic risk factors crucial in managing obesity or overweight among patients with T2D. Both tirzepatide doses also had a generally similar safety profile to semaglutide.
Eli Lilly and Company
Article
Published version
English
Avaluació de resultats (Assistència sanitària); Posologia; Obesitat - Tractament; Diabetis no-insulinodependent - Tractament; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Obesity Agents; Other subheadings::Other subheadings::Other subheadings::/administration & dosage; DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Overweight; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2; Other subheadings::Other subheadings::Other subheadings::/drug therapy; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos antiobesidad; Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación; ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::hipernutrición::obesidad; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::peso corporal::sobrepeso; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Wiley
Diabetes, Obesity and Metabolism;27(9)
https://doi.org/10.1111/dom.16508
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
